BR112022026233A2 - Processo para sintetizar lipídios catiônicos - Google Patents

Processo para sintetizar lipídios catiônicos

Info

Publication number
BR112022026233A2
BR112022026233A2 BR112022026233A BR112022026233A BR112022026233A2 BR 112022026233 A2 BR112022026233 A2 BR 112022026233A2 BR 112022026233 A BR112022026233 A BR 112022026233A BR 112022026233 A BR112022026233 A BR 112022026233A BR 112022026233 A2 BR112022026233 A2 BR 112022026233A2
Authority
BR
Brazil
Prior art keywords
synthesizing
cation lipids
lipids
cation
targeting
Prior art date
Application number
BR112022026233A
Other languages
English (en)
Inventor
Louis Beutner Gregory
Carrasquillo-Flores Ronald
Lora Gonzalez Federico
J Smith Michael
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112022026233A2 publication Critical patent/BR112022026233A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups quaternised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCESSO PARA SINTETIZAR LIPÍDIOS CATIÔNICOS. A presente invenção refere-se a processos para sintetizar lipídios catiônicos de Fórmula I úteis na síntese de composições solúveis em gordura para direcionamento e aumento da atividade de moléculas terapêuticas, incluindo siRNA.
BR112022026233A 2020-06-24 2021-06-22 Processo para sintetizar lipídios catiônicos BR112022026233A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043518P 2020-06-24 2020-06-24
PCT/US2021/038524 WO2021262745A1 (en) 2020-06-24 2021-06-22 Process for synthesizing cationic lipids

Publications (1)

Publication Number Publication Date
BR112022026233A2 true BR112022026233A2 (pt) 2023-01-17

Family

ID=79281775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026233A BR112022026233A2 (pt) 2020-06-24 2021-06-22 Processo para sintetizar lipídios catiônicos

Country Status (11)

Country Link
US (1) US20230265050A1 (pt)
EP (1) EP4171578A4 (pt)
JP (1) JP2023532014A (pt)
KR (1) KR20230042022A (pt)
CN (1) CN115996730A (pt)
AU (1) AU2021297806A1 (pt)
BR (1) BR112022026233A2 (pt)
CA (1) CA3183536A1 (pt)
IL (1) IL299271A (pt)
MX (1) MX2022016523A (pt)
WO (1) WO2021262745A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59380B1 (sr) * 2011-06-08 2019-11-29 Nitto Denko Corp Jedinjenja za ciljanje isporuke leka i pojačavanje sirnk aktivnosti
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
DK2858974T3 (en) * 2012-06-08 2018-12-03 Nitto Denko Corp LIPIDS FOR THERAPEUTIC MEDICINE DELIVERY FORMULATIONS
ES2821966T3 (es) * 2014-04-02 2021-04-28 Nitto Denko Corp Molécula de direccionamiento derivada de RBP y utilización de la misma
TW201701887A (zh) * 2015-02-19 2017-01-16 日東電工股份有限公司 抗伊波拉（Ｅｂｏｌａ）病毒之ＲＮＡ干擾治療劑

Also Published As

Publication number Publication date
IL299271A (en) 2023-02-01
CA3183536A1 (en) 2021-12-30
CN115996730A (zh) 2023-04-21
US20230265050A1 (en) 2023-08-24
KR20230042022A (ko) 2023-03-27
JP2023532014A (ja) 2023-07-26
AU2021297806A1 (en) 2023-02-23
EP4171578A4 (en) 2024-08-07
WO2021262745A1 (en) 2021-12-30
MX2022016523A (es) 2023-01-30
EP4171578A1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
BR112023016299A2 (pt) Composições e métodos para inibir kras
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BRPI0511072B8 (pt) compostos derivados de alquinila como moduladores dos receptores de glutamato metabotróbico, seus usos e suas composições farmacêuticas
MX2022001770A (es) Vesícula extracelular unida a moléculas y usos de esta.
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
BR112015011298A2 (pt) inibidores de cotransportador 1 de glicose de sódio
BR112015021856A2 (pt) processos e intermediários para a preparação de um medicamento
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR0212613A (pt) Compostos de indazol substituìdos para o tratamento de inflamação
BR112023000047A2 (pt) Compostos de ureia tricíclicos como inibidores da v617f da jak2
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112022019532A2 (pt) Conjugados de neodegrader
PE20230077A1 (es) Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
BR112013029640A2 (pt) derivados de piridina e pirazina
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
MX362571B (es) Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
BR112015025543A2 (pt) processo para a preparação de (3r,4r)-(l-benzil-4-metilpiperidina-3-il)- metilamina e compostos
CU23848B1 (es) Derivados de octahidrofenantreno n(2-metilpiridino-3-il) carboxamida útiles como moduladores de receptor de glucocorticoides
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0607309A2 (pt) processos para a preparação de fenilpirazol uréias substituìdas
CO6910188A2 (es) Productos para el cuidado del cabello con mayores rendimientos de cuidado
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos